Is hydroxyzine (Vistaril) safe for patients with cardiac disease or a history of heart problems?

Hydroxyzine (Vistaril) Should Be Used with Significant Caution in Cardiac Patients Due to Risk of QT Prolongation and Arrhythmias

Hydroxyzine is NOT safe for routine use in patients with cardiac disease, particularly those with pre-existing heart conditions, recent myocardial infarction, heart failure, bradyarrhythmias, or risk factors for QT prolongation. 1

Key Cardiac Risks

The FDA label explicitly warns that hydroxyzine can cause:

• QT prolongation and Torsade de Pointes (TdP) - documented in post-marketing surveillance 1
• The majority of these cases occurred in patients with pre-existing cardiac risk factors 1
• Case reports confirm hydroxyzine-induced TdP even at low doses (12.5 mg) in vulnerable patients 2

High-Risk Cardiac Populations Who Should Avoid Hydroxyzine

Contraindicated or use extreme caution in:

• Congenital long QT syndrome or family history of long QT 1
• Recent myocardial infarction 1
• Uncompensated heart failure 1
• Bradyarrhythmias or complete heart block 1, 2
• Patients on QT-prolonging medications (Class IA/III antiarrhythmics, certain antipsychotics, SSRIs like citalopram, macrolide antibiotics, methadone) 1
• Electrolyte imbalances 1

Guideline Perspective on Antihistamines in Cardiovascular Disease

The 2024 AHA palliative care guideline for cardiovascular disease does NOT recommend hydroxyzine for anxiety or insomnia in patients with end-stage cardiovascular disease. Instead, the guideline recommends 3:

• SSRIs (particularly sertraline) for anxiety/depression - lower QT risk than citalopram/escitalopram
• Cognitive behavioral therapy as first-line for insomnia
• Mirtazapine or trazodone for sleep if pharmacotherapy needed
• Avoidance of medications with significant cardiovascular side effects

The 2019 mast cell disorders guideline specifically notes "concern about use [of first-generation antihistamines like hydroxyzine] in patients prone to cardiovascular events" 4, and warns about cognitive decline particularly in elderly patients who often have cardiac comorbidities 4.

Clinical Evidence of Harm

• An 82-year-old with complete AV block developed TdP after just 12.5 mg hydroxyzine during pacemaker implantation 2
• A 9-year-old developed supraventricular tachycardia on therapeutic doses 5
• Historical data from 1975 warns of abnormal ventricular repolarization, with increased risk when combined with other cardiac medications 6
• UK regulatory advisories in 2015 led to a 21% decrease in hydroxyzine prescribing due to arrhythmia concerns 7

Safer Alternatives for Cardiac Patients

For anxiety:

• Sertraline (SSRI with lower QT risk) 3
• Mirtazapine (shown safe in CVD, though efficacy data limited) 3

For insomnia:

• Cognitive behavioral therapy first-line 3
• Trazodone or mirtazapine if sedating antidepressant needed 3
• Melatonin receptor agonists (ramelteon) 3

For pruritus/allergic symptoms:

• Second-generation antihistamines (fexofenadine, cetirizine) have better cardiac safety profiles 4

Critical Caveat

The one older study suggesting hydroxyzine was "well tolerated and safe" in 55 cardiovascular patients 8 is from 1999, predates the FDA warnings about QT prolongation, and is contradicted by subsequent case reports, regulatory advisories, and the current FDA label. This study should not guide current practice.

Bottom Line Algorithm

1. Does patient have ANY cardiac history or risk factors? → Choose alternative agent
2. Is hydroxyzine absolutely necessary? → Obtain baseline ECG, check electrolytes, review medication list for QT-prolonging drugs
3. Elderly patient? → Start lowest dose, monitor closely for sedation and cardiac effects 1
4. Bradycardia present? → Do not use 2